Business
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update. Third Quarter and Recent Highlights During the third quarter and subseq
About this update from Heartsciences Inc.
[{"type":"image","alt":"HeartSciences Inc.","displaySize":"","headline":null,"caption":"HeartSciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":271,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/bb8c6c7931166e53de866ed1f7dbdc1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQBZp3ueg1_7du_2jEqWig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/bb8c6c7931166e53de866ed1f7dbdc1d","width":271,"height":58}},"lazy":false},{"type":"text","content":"Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update.","length":434,"tagName":"p"},{"type":"text","content":"Third Quarter and Recent Highlights","length":35,"tagName":"p"},{"type":"text","content":"During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.","length":274,"tagName":"p"},{"type":"text","content":"MyoVista Insights™ Healthcare IT Software Platform","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Regulatory classification. MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements than medical devices and is exempt from FDA 510(k) clearance. As a result, organizational costs and time to commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.","length":389,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":389,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Platform advancement. Since its early-adopter launch in 2025, the Company has implemented phased upgrades to MyoVista Insights. On March 13, 2026, HeartSciences released a significant version upgrade ahead of the American College of Cardiology (“ACC”) A...